NDI Notifications Are Not Swept Aside As New Drugs – FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA’s rejection of PharmaRoth Labs’ Sucanon NDI notifications included a suggestion that the firm try the investigational new drug pathway, but is not a sign of a growing trend at the agency.
You may also be interested in...
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.
Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient
FDA rejects Ovos Natural Health's citizen petition to classify homotaurine as a dietary ingredient, but leaves the door open for future attempts on the pathway Ovos tried to navigate – moving a substance from failed investigational new drug to dietary supplement.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”